What can be hidden under the mask of unspecified hepatitis: a clinical observation and a literature review


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background. Sarcoidosis is an immunoinflammatory multisystem disease of unknown etiology. In sarcoidosis, the lungs are most commonly affected, while the liver is the third most commonly affected organ in a systemic process. Isolated liver damage is rare. The diagnosis of hepatic sarcoidosis (HS) is difficult, most cases of liver damage in sarcoidosis are clinically asymptomatic, extremely rarely patients develop icterus, chronic cholestasis, portal hypertension (PH) without cirrhotic transformation. In this case, the diagnosis of HS depends on the histological evaluation. Description of the clinical case. We present a clinical case of HS complicated by non-cirrhotic PH. There are not many reports of PH complicating HS. An important aspect that attracts attention is the complex pathogenesis of sarcoidosis, the presence of non-cirrhotic PH in a patient with HS without cirrhosis, and as fibrosis progresses, the possibility of increasing pressure in the portal vein system, so PH will be mixed etiology. Conclusion. The purpose of the publication of our clinical observation is drawing the attention of practitioners, gastroenterologists to the problem of the inadmissibility of the existence of a diagnosis of «unspecified hepatitis», the need to verify the diagnosis by all possible methods already at the first visit of the patient.

Full Text

Restricted Access

About the authors

E. V Vinnitskaya

A.S. Loginov Moscow Clinical Research and Practical Center of the Moscow Healthcare Department

Yulia G. Sandler

A.S. Loginov Moscow Clinical Research and Practical Center of the Moscow Healthcare Department

Email: at.sandler@mknc.ru
Cand. Sci. (Med.), Senior Researcher at the Research Department of Hepatology

G. V Belyaev

A.S. Loginov Moscow Clinical Research and Practical Center of the Moscow Healthcare Department

T. Yu Khaimenova

A.S. Loginov Moscow Clinical Research and Practical Center of the Moscow Healthcare Department

S. G Khomeriki

A.S. Loginov Moscow Clinical Research and Practical Center of the Moscow Healthcare Department

References

  1. Crouser E.D., Maier L.A., Wilson K.C., et al. Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline. Am J. Respir Crit Care Med. 2020;201(8):e26-e51. doi: 10.1164/rccm.202002-0251ST.
  2. Саркоидоз: Монография под ред. Визеля А.А. (Серия монографий Российского респираторного общества; гл. ред. серии Чучалин А.Г). М.: Атмосфера, 2010.416c.
  3. Ghoneim S., Williams S.D. Hepatic Sarcoidosis: An Uncommon Cause of Cirrhosis. Cureus. 2019;11(12):e6316. doi: 10.7759/cureus.6316.
  4. Визель А.А., Визель И.Ю. Современные аспекты эпидемиологии саркоидоза. Пульмонология. 2010;(6):104-8. doi: 10.18093/0869-0189-2010-6-104-108.
  5. Grunewald J., Grutters J.C., Arkema E.V., et al. Sarcoidosis. Nat Rev Dis Primers. 2019;5(1):45. doi: 10.1038/s41572-019-0096-x.
  6. Syed U., Alkhawam H., Bakhit M., et al. Hepatic sarcoidosis: pathogenesis, clinical context, and treatment options. Scand J. Gastroenterol. 2016;51:1025-30.
  7. Baughman R.P., Teirstein A.S., Judson M.A., et al. Clinical characteristics of patients in a case control study of sarcoidosis. Case Control Etiologic Study of Sarcoidosis (ACCESS) research group. Am J. Respir Crit Care Med. 2001;164:1885-89.
  8. James WE, Koutroumpakis E., Saha B., et al. Clinical features of extrapulmonary sarcoidosis without lung involvement. Chest 2018;154:349-56. doi: 10.1016/j.chest.2018.02.003.
  9. Rizzato G., Palmieri G., Agrati A.M., et al. The organ-specific extrapulmonary presentation of sarcoidosis: a frequent occurrence but a challenge to an early diagnosis. A 3-year-long prospective observational study. Sarcoidosis Vasc Diffuse Lung Dis 2004;21:119-26.
  10. Ghanim M.T., Tiwari A., Nawras A. Hepatic Sarcoidosis Suspected for Liver Cirrhosis-A Case Report of Diagnosing Subclinical Disease. Am J. Gastroenterol. 2018;113(suppl.):S1256. doi: 10.14309/00000434-201810001-02209.
  11. Grunewald J., Grutters J.C., Arkema E.V., et al. Sarcoidosis. Nat Rev Dis Primers. 2019;5(1):45. doi: 10.1038/s41572-019-0096-x. Erratum in: Nat Rev Dis Primers. 2019 Jul 16;5(1):49.
  12. Newman K.L., Newman L.S. Occupational causes of sarcoidosis. Curr Opin Allergy Clin immunol. 2012;12(2):145-50. Doi: 10.1097/ ACi.0b013e3283515173.
  13. Drake W.P., Newman L.S. Mycobacterial antigens may be important in sarcoidosis pathogenesis. Curr Opin Pulm. Med. 2006;12:359-63. doi: 10.1097/01.mcp.0000239554.01068.94.
  14. Ramos-Casals M., Mana J., Nardi N., et al. Sarcoidosis in patients with chronic hepatitis c virus infection: Analysis of 68 cases. Medicine. 2005;84:69-80. doi: 10.1097/01.md.0000157577. 69729.e6.
  15. Starshinova A.A., Malkova A.M., Basantsova N.Y., et al. Sarcoidosis as an autoimmune disease. Front immunol. 2019;10:2933. Doi: 10.3389/ fimmu.2019.02933.
  16. Georas S.N., Chapman T.J., Crouser E.D. Sarcoidosis and T-Helper Cells. Th1, Th17, or Th17.1? Am J. Respir Crit Care Med. 2016;193(11):1198-200. doi: 10.1164/rccm.201512-2419ED.
  17. Sakthivel P., Bruder D. Mechanism of granuloma formation in sarcoidosis. Curr Opin Hematol. 2017;24(1):59-65. Doi: 10.1097/ M0H.0000000000000301. PMID: 27755127.
  18. Прокопчик Н.И., Цыркунов В.М. Саркоидоз печени. Гепатология и гастроэнтерология. 2019;3(2):206-11. doi: 10.25298/2616-5546-2019-3-2-206-211.
  19. Ebert E.C., Kierson M., Hagspiel K.D. Gastrointestinal and hepatic manifestations of sarcoidosis. Am J. Gastroenterol. 2008;103(12):3184-92; quiz 3193. doi: 10.1111/j.1572-0241.2008.02202.x.
  20. Al-Kofahi K., Korsten P., Ascoli C., et al. Management of extrapulmonary sarcoidosis: challenges and solutions. Therapeutics and Clinical Risk Management. 2016;12:1623-1634. doi: 10.2147/tcrm.s74476.
  21. Jain R., Yadav D., Puranik N., Guleria R., Jun-O. Jin. Sarcoidosis: Causes, Diagnosis, Clinical Features, and Treatments. J. Clin Med. 2020;9(4):1081. doi: 10.3390/jcm9041081.
  22. Graf C., Arncken J., Lange C.M., et al. Hepatic sarcoidosis: Clinical characteristics and outcome. JHEP Rep. 2021;3(6):100360. Doi: 10.1016/j. jhepr.2021.100360.
  23. Kraaijvanger R., Janssen Bonas M., Vorselaars A.D.M., Veltkamp M. Biomarkers and diagnosis and prognosis of sarcoidosis: current use and future prospects. Front immunol. 2020;11:1443. doi: 10.3389/fimmu.2020.01443.
  24. Ramos-Casals M., Retamozo S., Siso-Almirall A., et al. Ciinicaiiy-usefui serum biomarkers for diagnosis and prognosis of sarcoidosis. Expert Rev Clin Immunol. 2019;15(4):391-405. doi: 10.1080/1744666X.2019.1568240.
  25. Sedki M., Fonseca N., Santiago P., Diaz L., et al. Hepatic Sarcoidosis: Natural History and Management Implications. Front Med (Lausanne). 2019;6:232. doi: 10.3389/fmed.2019.00232.
  26. Tadros M., Forouhar F., Wu GY Hepatic Sarcoidosis. J. Clin Transl Hepatol. 2013;1(2):87-93. doi: 10.14218/JCTH.2013.00016.
  27. Moreno-Merlo F., Wanless I.R., Shimamatsu K., et al. The role of granulomatous phlebitis and thrombosis in the pathogenesis of cirrhosis and portal hypertensionin sarcoidosis. Hepatology 1997;96:524-60.
  28. Russi E.W., Bansky G., Pfaltz M., et al. Budd-Chiari syndrome in sarcoidosis. Am J. Gastroenterol 1986;81:71-6.
  29. Kumar M., Herrera J.L. Sarcoidosis and the Liver Clin Liver Dis. 2019;23(2):331-43. Doi: 10.1016/ J. dd.2018.12.012.
  30. Blich M., Edoute Y. Clinical manifestations of sarcoid liver disease. J. Gastroenterol Hepatol. 2004;19(7):732-37. Doi: 10.1111/j. 1440-1746.2003.03336.x.
  31. Judson M.A. Extrapulmonary sarcoidosis. Semin Respir Crit Care Med. 2007;28(1):83-101. doi: 10.1066/s-2007-970336.
  32. Stanca C.M., Fiel M.I., Allina J., et al. Liver failure in an antimitochondrial antibody-positive patient with sarcoidosis: primary biliary cirrhosis or hepatic sarcoidosis? Semin Liver Dis. 2006;26(3):364-70. doi: 10.1066/s-2006-916327.
  33. Vanatta J.M., Modanlou K.A., Dean A.G., et al. Outcomes of orthotopic liver transplantation for hepatic sarcoidosis: an analysis of the United Network for Organ Sharing/Organ Procurement and Transplantation Network data files for a comparative study with cholestatic liver diseases. Liver Transpl. 2011;17(9): 1027-34. Doi: 10.1002/ lt.22339.
  34. Beegle S.H., Barba K., Gobunsuy R., Judson M.A. Current and emerging pharmacological treatments for sarcoidosis: a review. Drug Des Devel Ther. 2013;7:326-38. doi: 10.2147/DDDTS31064.
  35. Gerke A.K. Treatment of Sarcoidosis: A Multidisciplinary Approach. Front Immunol. 2020;11:646413. Doi:10.3389/ fimmu.2020.646413.
  36. De Mulder P., Maertens B., Hoorens A., Vonck A. Extrapulmonary sarcoidosis primarily presenting as cholestatic liver disease. BMJ Case Rep. 2019;12(12):e232618. doi: 10.1136/bcr-2019232618.
  37. Baratta L., Cascino A., Delfino M., et al. Ursodeoxycholic acid treatment in abdominal sarcoidosis. Dig Dis Sci. 2000;46(8):1669-62. doi: 10.1023/a:1006660927060
  38. Mueller S., Boehme M.W., Hofmann W.J., Stremmel W. Extrapulmonary sarcoidosis primarily diagnosed in the liver. Scand J. Gastroenterol. 2000;36(9):1003- 8. doi: 10.1080/003666200760023110.
  39. James W.E., Baughman R. Treatment of sarcoidosis: grading the evidence. Expert Rev Clin Pharmacol. 2018;11(7):677-87. doi: 10.1080/17612433.2018.1486706.

Supplementary files

Supplementary Files
Action
1. JATS XML

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies